Endo Pharmaceuticals, the US-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments - branded pharmaceuticals, generics and devices and services, has announced that the US Food and Drug Administration has approved its Felodipine Extended-release tablets USP, 2.5mg, 5mg and 10mg.

According to a company press release, Qualitest Pharmaceuticals, the generic business unit  of Endo Pharmaceuticals will manufacture and distribute the Felodipine Extended-release tablets.

Felodipine Extended-release tablets USP are the generic version of AstraZeneca's Plendil Extended-release tablets.

The total sales for Felodipine in the US for the 12 months ended June 30, 2011 were approximately $84 million, according to IMS Health.